- Home
- MTEX vs LPCN Comparison
MTEX vs LPCN Comparison
Compare MTEX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- LPCN
- Stock Information
- Founded
- MTEX 1993
- LPCN 1997
- Country
- MTEX United States
- LPCN United States
- Employees
- MTEX N/A
- LPCN N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- LPCN Health Care
- Exchange
- MTEX Nasdaq
- LPCN Nasdaq
- Market Cap
- MTEX 15.8M
- LPCN 16.1M
- IPO Year
- MTEX 1999
- LPCN N/A
- Fundamental
- Price
- MTEX $8.60
- LPCN $2.89
- Analyst Decision
- MTEX
- LPCN Strong Buy
- Analyst Count
- MTEX 0
- LPCN 2
- Target Price
- MTEX N/A
- LPCN $9.00
- AVG Volume (30 Days)
- MTEX 9.6K
- LPCN 16.6K
- Earning Date
- MTEX 11-11-2025
- LPCN 11-06-2025
- Dividend Yield
- MTEX N/A
- LPCN N/A
- EPS Growth
- MTEX N/A
- LPCN N/A
- EPS
- MTEX N/A
- LPCN N/A
- Revenue
- MTEX $112,975,000.00
- LPCN $4,208,119.00
- Revenue This Year
- MTEX N/A
- LPCN N/A
- Revenue Next Year
- MTEX N/A
- LPCN N/A
- P/E Ratio
- MTEX N/A
- LPCN N/A
- Revenue Growth
- MTEX N/A
- LPCN N/A
- 52 Week Low
- MTEX $7.05
- LPCN $2.68
- 52 Week High
- MTEX $16.49
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- MTEX 49.32
- LPCN 44.03
- Support Level
- MTEX $7.80
- LPCN $2.85
- Resistance Level
- MTEX $9.75
- LPCN $3.08
- Average True Range (ATR)
- MTEX 0.86
- LPCN 0.10
- MACD
- MTEX -0.02
- LPCN 0.00
- Stochastic Oscillator
- MTEX 30.19
- LPCN 20.90
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.